Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status.
India has granted emergency approval to COVID-19 vaccines developed by AstraZeneca and Oxford University and one from the state-run institute Bharat Biotech, ahead of a huge immunisation drive that is planned to begin this week.
Teva Pharmaceuticals has failed to redefine its multiple sclerosis drug Copaxone as a biological product instead of a drug, after the US District Court for the District of Columbia dismissed its efforts as “uncompetitive” on December 31.
Aurobindo’s subsidiary Eugia allegedly infringed two patents for an injectable treatment for reducing the risk of premature birth, according to a lawsuit by Covis Pharma, a Luxembourg-based unit of Apollo Global Management.
One of the architects of the Hatch-Waxman Act has urged judges to reverse a decision which he says nullifies a key provision of the generic drug legislation.
Canadian medical cannabis company Canopy Growth has accused GW Pharma of using a patented technological process to produce its flagship epilepsy treatment, Epidiolex, without authorisation.
A manufacturer of healthcare products including personal protective equipment has accused a newly incorporated company of trying to confuse consumers during the Covid-19 pandemic.
A US federal appeals court has upheld a 42-month prison sentence for an ex-employee of DuPont Industrial Biosciences who stole trade secrets from the firm.
Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
Biogen has lost its long-standing fight to recover billions of dollars in royalties from the sale of a multiple sclerosis (MS) drug, after the US Court of Appeals for the Federal Circuit rejected Biogen’s request that it reconsider its own ruling.